Beclin1-induced Autophagy Abrogates Radioresistance of Lung Cancer Cells by Suppressing Osteopontin
Article 2012 en
Authors
SC
Seung-Hee Chang
AM
Arash Minai‐Tehrani
JS
Ji‐Young Shin
Abstract
1 min read
Abstract Osteopontin (OPN) serves as an indicator of resistance to radiotherapy. However, the role of OPN in the development of acquired radioresistance in human lung cancer cells has not yet been fully elucidated. Therefore, the potential importance of OPN as a marker of lung cancer with a potential significant role in the development of radioresistance against repeated radiotherapy has prompted us to define the pathways by which OPN regulates lung cancer cell growth. In addition, autophagy has been reported to play a key role in the radiosensitization of cancer cells. Here, we report that increased OPN expression through induction of nuclear p53 following irradiation was inhibited by exogenous beclin-1 (BECN1). Our results clearly show that BECN1 gene expression led to induction of autophagy and inhibition of cancer cell growth and angiogenesis. Our results suggest that the induction of autophagy abrogated the radioresistance of the cancer cells. Interestingly, we showed that knockdown of OPN by lentivirus-mediated shRNA induced the autophagy of human lung cancer cell. Taken together, these results suggest that OPN and BECN1 can be molecular targets for overcoming radioresistance by controlling autophagy.
Arash Minai‐Tehrani, Seung-Hee Chang, Jung‐Taek Kwon, Soon‐Kyung Hwang, Ji‐Eun Kim, Ji‐Young Shin, Kyeong‐Nam Yu, Sung Jin Park, Hu‐Lin Jiang, Jihye Kim, Seongho Hong, Bitna Kang, Duyeoul Kim, Chanhee Chae, Kee-Ho Lee, George R. Beck, Myung‐Haing Cho
A.T.Y. Ko, A Kanehisa, Isabelle Martins, Laura Senovilla, Cyrus Chargari, Delphine Dugué, Guillermo Mariño, Oliver Kepp, Michael Michaud, Jean‐Luc Perfettini, Guido Guido Kroemer, Éric Deutsch
Federico Pietrocola, Jonathan Pol, Erika Vacchelli, Elisa Elena Baracco, Sarah Lévesque, Francesca Castoldi, Maria Chiara Maiuri, Frank Madeo, Guido Guido Kroemer
Discussion(0)
No comments yet. Be the first to comment.